Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program

DOI: 10.4143/crt.2016.067

Keywords: Regorafenib, Gastrointestinal stromal tumors, Management access program, Failure to imatinib, Sunitinib

Full-Text   Cite this paper   Add to My Lib

Abstract:

The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients

Full-Text